Get the Stockscreener App
2.61
0.00%
0.00
C 4 Therapeutics Inc stock is traded at $2.61, with a volume of 928.44K.
It is up +0.00% in the last 24 hours and up +17.57% over the past month.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
See More
Previous Close:
$2.61
Open:
$2.62
24h Volume:
928.44K
Relative Volume:
0.64
Market Cap:
$185.76M
Revenue:
$20.76M
Net Income/Loss:
$-132.49M
P/E Ratio:
-0.9775
EPS:
-2.67
Net Cash Flow:
$-108.55M
1W Performance:
+6.10%
1M Performance:
+17.57%
6M Performance:
-13.29%
1Y Performance:
-56.93%
1-Day Range:
$2.60
$2.755
1-Week Range:
$2.46
$3.065
52-Week Range:
$1.085
$7.22
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Name
C 4 Therapeutics Inc
Sector
Industry
Phone
(617) 231-0700
Address
490 ARSENAL WAY, WATERTOWN
Compare CCCC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.61 | 203.55M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-18-24 | Initiated | Stephens | Equal-Weight |
| Jan-29-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-13-23 | Upgrade | Stifel | Hold → Buy |
| Feb-24-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-24-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Underweight |
| Apr-28-22 | Initiated | Credit Suisse | Underperform |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-10-22 | Initiated | JP Morgan | Overweight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Nov-23-21 | Initiated | BofA Securities | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-27-20 | Initiated | BMO Capital Markets | Outperform |
| Oct-27-20 | Initiated | Jefferies | Buy |
View All
C 4 Therapeutics Inc Stock (CCCC) Latest News
C4 Therapeutics Inc. Bounces Off Moving Average Support2025 Historical Comparison & Safe Capital Growth Plans - thegnnews.com
Using Bollinger Bands to evaluate C4 Therapeutics Inc.2025 Big Picture & AI Powered Trade Plan Recommendations - Newser
Visual trend scoring systems applied to C4 Therapeutics Inc.Quarterly Profit Review & Capital Efficiency Focused Strategies - Newser
Is C4 Therapeutics Inc. forming a reversal patternTrade Risk Summary & Low Drawdown Trading Strategies - Newser
Detecting support and resistance levels for C4 Therapeutics Inc.July 2025 Action & Fast Entry and Exit Trade Plans - Newser
Market reaction to C4 Therapeutics Inc.’s recent newsMarket Risk Analysis & Smart Allocation Stock Reports - Newser
What analysts say about C4 Therapeutics Inc. stock outlookWeekly Volume Report & Free AI Powered Buy and Sell Recommendations - Newser
Stoke Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Real time breakdown of C4 Therapeutics Inc. stock performanceJuly 2025 Decliners & Fast Exit Strategy with Risk Control - Newser
What the charts say about C4 Therapeutics Inc. todayWeekly Loss Report & Reliable Price Breakout Alerts - Newser
C4 Therapeutics Inc. Breakout Confirmed by Volume MetricsVolume Spike & Entry Point Confirmation Signals - beatles.ru
How does C4 Therapeutics Inc. compare to its peersJuly 2025 Pullbacks & Real-Time Sentiment Analysis - thegnnews.com
Is C4 Therapeutics Inc. stock ready for a breakout2025 Trading Volume Trends & Expert Approved Momentum Trade Ideas - Newser
How hedge fund analytics apply to C4 Therapeutics Inc. stockRecession Risk & Low Risk High Reward Ideas - Newser
Long term hold vs stop loss in C4 Therapeutics Inc.July 2025 Update & Short-Term Swing Trade Alerts - Newser
What is the dividend yield of C4 Therapeutics Inc.Quarterly Portfolio Review & Free Fast Gain Swing Trade Alerts - thegnnews.com
XTX Topco Ltd Makes New Investment in C4 Therapeutics, Inc. (NASDAQ:CCCC) - Defense World
How institutional ownership impacts C4 Therapeutics Inc. stock2025 Trading Recap & Risk Controlled Stock Alerts - Newser
How to manage a losing position in C4 Therapeutics Inc.2025 Top Decliners & Short-Term Swing Trade Alerts - Newser
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Why is C4 Therapeutics Inc. stock going downDay Trading 5x Gain Picks - mustnews.co.kr
Akamis Bio Announces the Appointment of Andrew Hirsch to the Company’s Board of Directors - Business Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Why C4 Therapeutics Inc. stock attracts strong analyst attentionStock Forecast Tools for Retail Traders - Newser
Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
What earnings revisions data tells us about C4 Therapeutics Inc.Free Growth Based Investment Plan Guidance - Newser
How to integrate C4 Therapeutics Inc. into portfolio analysis toolsWeekly Gain Forecast with Momentum Indicators - Newser
New Product Launches: Will They Boost C4 Therapeutics Inc. Stock in 2025Smart Swing Picks with Confirmed Signals - Newser
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics 2025 Q2 Earnings Widened Losses Amid Mixed Price Performance - AInvest
Spotlight On 3 Intriguing Penny Stocks With Market Caps As Low As $100M - simplywall.st
C4 Therapeutics, Inc. (NASDAQ:CCCC) Surges 51% Yet Its Low P/S Is No Reason For Excitement - 富途牛牛
C4 Therapeutics Reports Q2 2025 Financial Results - TipRanks
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics Q2 2025 Financial Results: Revenue Down to $6.5M, Cash Position at $223M - AInvest
C4 Therapeutics shares surge 22.96% intraday after positive clinical trial results and strong Q2 earnings. - AInvest
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
C4 Therapeutics, Inc. SEC 10-Q Report - TradingView
C4 Therapeutics reports Q2 2025 results, cemsidomide Phase 1 data accepted at IMS. - AInvest
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
C4 Therapeutics shares rise 1.02% premarket after Ono Pharmaceutical's ESG index selection. - AInvest
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics (CCCC) Projected to Post Quarterly Earnings on Thursday - Defense World
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Astria Therapeutics Grants Stock Options to Two New Employees Under Nasdaq Listing Rule 5635(c)(4) - AInvest
C 4 Therapeutics Inc Stock (CCCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
C 4 Therapeutics Inc Stock (CCCC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Boyle Scott N | Chief Business Officer |
Feb 14 '25 |
Sale |
3.15 |
490 |
1,544 |
110,842 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):